

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: Wesana Health Holdings Inc. (the "Issuer").

Trading Symbol: WESA

Number of Outstanding Listed Securities: 19,329,189

Date: April 5, 2022 (Reporting period – March 2022)

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

Following the completion of the reverse takeover transaction ("RTO Transaction") in May 2021, the Issuer has been focused on the research and development of drug therapies using high dose psilocybin-assisted psychotherapy and psilocybin in a low dose, non-hallucinogenic form to treat traumatic brain injury ("TBI"), and specifically the TBI associated symptoms, such as (i) anxiety, (ii) depression, and (iii) migraine. This is more fully described in the Issuer's Listing Statement posted to the Exchange website on May 10, 2021.

On March 8, 2022, the Issuer announced that Amendment to Preliminary Shelf Prospectus (NI 44-102) dated December 13, 2021, was withdrawn as filed on Sedar.

In a press release dated March 11, 2022, the Issuer provided an update on the build-out of a third clinic (located in Naperville, Illinois), including that the construction is underway, with a target open date in Spring 2022.

In a press release dated March 14, 2022, the Issuer announced that they have received a written response from the Food and Drug Administration (FDA) regarding their pre-Investigational New Drug (IND) meeting for the novel therapy and proprietary protocol of SANA-013 for the treatment of TBI related major depressive disorder (MDD).

In a press release dated March 22, 2022, the Issuer announced findings from a validated animal study, conducted by an independent global laboratory services provider, indicating psilocybin may potentiate impact of an anti-depressant.

In a press release dated March 29, 2022, the Issuer announced that its CEO Carcillo to speak at several leading investor and industry events.

2. Provide a general overview and discussion of the activities of management.

See response to question no. 1, above.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

See response to question no. 1, above.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

N/A

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

N/A

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

N/A

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

N/A

8. Describe the acquisition of new customers or loss of customer

N/A

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

N/A

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

N/A

11. Report on any labour disputes and resolutions of those disputes if applicable.

N/A

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

N/A

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

N/A

14. Provide details of any securities issued and options or warrants granted.

<i>Security</i>	<i>Number issued</i>	<i>Details of Issuance</i>	<i>Use of Proceeds</i>
N/A	N/A	N/A	N/A
N/A	N/A	N/A	N/A

15. Provide details of any loans to or by Related Persons.

N/A

16. Provide details of any changes in directors, officers or committee members.

N/A

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

N/A.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: April 5, 2022.

Zed Wang

Name of Director or Senior
Officer

/s/ "Zed Wang"

Signature

Chief Financial Officer

Official Capacity

Issuer Details Name of Issuer Wesana Health Holdings Inc.	For Month End March 2022	Date of Report YY/MM/DD 2022/04/05
Issuer Address 433 W Van Buren St., Suite 200, Chicago, IL		
City/Province/Postal Code Chicago, IL, 60607	Issuer Fax No. ()	Issuer Telephone No. 773-236-7972
Contact Name Daniel Carcillo	Contact Position CEO	Contact Telephone No. 773-236-7972
Contact Email Address IR@wesanahealth.com	Web Site Address https://www.wesanahealth.com	